Perspective, Results

Bispecifics vs CAR-T: Analysts select the big winners — and losers — at #ASH18’s biggest ever datapalooza

/>

by — on

Analysts are having a field day comparing notes on a slew of data that emerged at ASH over the last few days. One standout seems to be a warm regard for much of the new data coming out on the wrangle for lead spot among BCMA bispecifics, with CAR-T slipping in comparison.

Jefferies' Michael Yee brought in a KOL to his investor lunch in San Diego and came away with this observation:

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 35,000+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription
Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA
Visit Endpoints Careers ->